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Charles Gore1, Stefan Wiktor2, David Goldberg3, Sharon Hutchinson4, Jose Antonio Oñate Moreno5
and Raquel Peck1*Abstract
The inaugural World Hepatitis Summit was jointly convened by the World Health Organization (WHO) and the
World Hepatitis Alliance and hosted by the Scottish Government and supported by Glasgow Caledonian University
and Health Protection Scotland in September 2015. The three day event convened a broad range of stakeholders
to meet and share ideas, experience and best practice in addressing the many facets of viral hepatitis prevention,
diagnosis and treatment.
With the next World Hepatitis Summit scheduled to take place from 1 to 3 November 2017, the World Hepatitis
Alliance asked Hepatology, Medicine and Policy to commission a roundtable discussion article in order to encourage
reflection on how the 2015 Summit was significant for stakeholders’ efforts and why it is important to keep the
momentum going ahead of the World Hepatitis Summit 2017 and in the light of the newly adopted first-ever
Global Health Sector Strategy on Viral Hepatitis.Background
Charles Gore, President of the World Hepatitis Alliance
The inaugural World Hepatitis Summit was jointly con-
vened by the World Health Organization (WHO) and the
World Hepatitis Alliance (WHA) and hosted by the
Scottish Government and supported by Glasgow Caledonian
University and Health Protection Scotland in September
2015. It was the first opportunity for a broad range of
policy-makers and patients to come together to discuss the
global response to viral hepatitis.
During three days of plenary sessions, panel discussions,
simulation exercises and other events, participants focused
on the central question of how to strengthen efforts to ad-
dress viral hepatitis at the national level through compre-
hensive national plans in line with World Health Assembly
Resolution 67.6. At the closing session, delegates endorsed
the Glasgow Declaration on Viral Hepatitis, which calls on
governments to develop and implement comprehensive* Correspondence: raquel.peck@worldhepatitisalliance.org
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(http://creativecommons.org/publicdomain/zenational hepatitis plans to drive action toward the elimin-
ation of viral hepatitis as a public health concern (Table 1).
With the next World Hepatitis Summit scheduled to
take place from 1 to 3 November 2017, it will be critical
once again to bring together a wide range of stakeholders
to accelerate action toward elimination. The World Hepa-
titis Alliance asked Hepatology, Medicine and Policy to
commission this roundtable discussion article in order to
encourage reflection on how the 2015 Summit was signifi-
cant for stakeholders’ efforts and why it is important to
keep the momentum going ahead of the World Hepatitis
Summit 2017. We are grateful to the diverse group of
World Hepatitis Summit 2015 delegates who responded to
the Alliance’s invitation to write roundtable contributions.World delegates initiate a global response to
hepatitis
Stefan Wiktor, Team Lead, Global Hepatitis Programme,
World Health Organization
The World Hepatitis Summit in 2015 was the inaugural
gathering of over 500 stakeholders. Key representatives,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Table 1 The Glasgow Declaration on Viral Hepatitis
Because there are 400 million people living with hepatitis B or hepatitis C
infection with no country/region unaffected,
Because there is a lack of global awareness and most persons with
hepatitis remain undiagnosed,
Because 1.4 million people die every year from complications of viral
hepatitis yet most of these deaths can be prevented,
Because there are highly effective measures to prevent new hepatitis B and
C infections and highly effective treatments that can suppress hepatitis B
virus replication and cure hepatitis C infection,
Because universal access to prevention, diagnosis, care and treatment is a
human right and promoting access to and affordability of these services is
the responsibility of all stakeholders,
The participants of the inaugural World Hepatitis Summit believe it is
possible and essential to set as a goal the elimination of both hepatitis
B and C as public health concerns. We therefore call upon governments
in all jurisdictions to develop and implement comprehensive, funded
national hepatitis plans and programmes in partnership with all
stakeholders and in line with the World Health Assembly Resolution 67.6
and, in collaboration with the World Health Organization, to define and
agree on realistic yet aspirational global targets for prevention, testing,
diagnosis, care and treatment.
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funders, public health specialists and others, contributed
to the global hepatitis discourse during the broad array
of sessions offered. By bringing together these diverse
groups, the Summit was able to promote collaboration
in the efforts to combat viral hepatitis—an approach that
is aligned with WHO’s aim to achieve equitable and ac-
cessible hepatitis services for all. In particular, patient
involvement helped to define the scope of the Summit
and was seen as crucial to its success.
Importantly, the Summit proved to be an ideal venue
for the release of the Glasgow Declaration on Viral
Hepatitis which initiated a momentum amongst patients
and WHO Member States, which was strengthened by
the extensive stakeholder consultations around WHO’s
Global Health Sector Strategy on Viral Hepatitis (GHSS).
The GHSS, which was adopted at the World Health
Assembly in May 2016, supports this overall vision
and outlines a set of targets and strategic priorities to
meet the goal.
The Glasgow meeting also provided an opportunity
for WHO to showcase and enable the implementation of
the normative guidance and technical assistance offered
by different teams and departments within WHO Head-
quarters and the Regional Offices. As the theme of the
Summit was “National Planning for Viral Hepatitis,” the
Summit directly supported the World Health Assembly
resolution 67.6, which calls on WHO “to provide the
necessary technical support to enable Member States
to develop robust national viral hepatitis prevention,
diagnosis and treatment strategies.”
The Summit was successful in raising the visibility of
viral hepatitis and increasing awareness among Member
State policy-makers of the importance of a comprehen-
sive response. It also served as an effective learningforum, providing many of the tools necessary for na-
tional planning for viral hepatitis.
Patients and policy-makers unite to eliminate viral
hepatitis
“But the importance of good data in making the
odyssey a success should not be underestimated”
Professors David Goldberg and Sharon Hutchinson,
Health Protection Scotland and Glasgow Caledonian
University
The first World Hepatitis Summit was a historic event
whose impact will become apparent in the future. A
brand has been established, a declaration to eliminate
hepatitis as a serious public health concern has been
voiced. A statement has been made about the importance
of civil society and politicians collaborating in the process
of service development and delivery. But what next?
The Summit represents a starting point—a platform, a
foundation, on which WHO and WHA can build a
highly visible movement to call attention to and promote
the miraculous advances in hepatitis B and C therapeutics
and primary prevention interventions. But the Summit
also reminded us that more needs to be done and that a
coordinated effort is vital. Future Summits, to be held
every two years, should serve as a key opportunity to bring
a wide range of stakeholders together and track progress
made in improving hepatitis services.
Because the Summit is about civil society, patients,
public health specialists and policy-makers, and not just
the latter, it is well placed to do this job. Patient (represen-
tative) power, in particular, as demonstrated in Portugal
and Scotland in relation to hepatitis C in 2007 and 2015,
respectively, might ultimately be the decisive factor in
making governments act. But without reliable process and
outcome data, both patients and policy-makers will find it
difficult to make the case for such investment.
Obtaining serial outcome data on the number of people
presenting with, or dying from, end stage liver disease is
crucial to identify the seriousness, scale and trajectory of
the problem, and to assess the intensity and type of inter-
vention(s) required to address it. As observed in Scotland
during 2007–08, politicians and civil servants became
much more engaged when confronted with observed data
on life-threatening disease and death than with estimated
data on the number of people with HCV infection.
Securing serial process data on the number and type
(especially from a liver disease stage perspective) of
people treated with anti-viral therapy is vital if a stra-
tegic approach to morbidity and mortality reduction is
to be achieved. For example, in the context of limited
healthcare resources and expensive therapies, intelligent,
prioritized prescribing—focusing on those at greatest
risk to health—will likely lead to a faster reduction in
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Health Organization’s Global Health Sector Strategy
underpinned by 2021 and 2030 elimination targets
(adopted in May 2016), will undoubtedly advance the
cause; however, currently, few countries are in an ad-
equately data-rich position to calibrate a proportionate
response consistent with WHO’s elimination vision. This
is because of insufficient resources and/or a failure to
fully appreciate the important role of surveillance/
monitoring tools in optimizing the efficiency of deploying
government funds to improve the health of the population
as a whole. Nevertheless, 2016 should be for hepatitis B
and C and associated end-stage disease what 1997 was for
HIV and AIDS—a signal year indicating that, at last, we
are on the road to disease elimination. The World
Hepatitis Summit is a start toward that goal.
World Hepatitis Summit strengthens patient power
Jose Antonio Oñate Moreno, Director, Fundación Hepatos
Aión, AC
Humanity is facing a great challenge, which can be solved
effectively only through global collaboration: the control
and elimination of viral hepatitis, particularly hepatitis B
and C. Nowhere has the urgency of this challenge been
highlighted so clearly as at the first World Hepatitis Sum-
mit. For patients and policy-makers alike, this event
underscored the need for immediate, and united, action to
confront and slow the spread of viral hepatitis.
The involvement of patient organizations demon-
strated the important consideration that the medical
community needs to give to hepatitis patients—those
whose lives have been greatly transformed by their expe-
riences living with the virus. The Summit provided these
organizations an opportunity to speak on behalf of those
who too frequently have been left out of crucial hepatitis
conversations and who are now vital partners in helping
create plans for effective prevention, treatment and care.
A number of Latin American patient organizations
were in attendance and benefited from networking and
exchanging ideas with other WHA member organiza-
tions. Topics were wide-ranging, from local and regional
strategies and best practices, to ways of partnering on
initiatives. They also consolidated their work through
their regional network, Hepared Latinoamerica. Those
of us from Mexico, where hepatitis takes the lives of
over 11,000 people annually, agreed to strengthen col-
laboration with local and regional health authorities to
implement a national strategy in 2016 to address viral
hepatitis. We also resolved to ensure that patients have
access to affordable direct-acting antivirals for hepatitis
C. The benefits of attending the conference have become
even more apparent to us in the past year.
United by a common goal, all participants at the Summit
benefited from the unique and very potent opportunity tointeract with others in attendance. The participation of pa-
tient organizations, representing the interests of those most
directly affected by viral hepatitis, was instrumental in mak-
ing their experiences and needs known. Their contributions
to the global discussion are vital to helping eventually elim-
inate hepatitis B and C. Ongoing partnerships among
health authorities, medical societies and civil service and
patient organizations at a local level will help ensure global
success in efforts to benefit all patients worldwide.
The beginning of the end of viral hepatitis
Raquel Peck, Chief Executive Officer, World Hepatitis
Alliance
The World Hepatitis Summit marked a pivotal moment
on the road to eliminating viral hepatitis. For the first time,
patients and policy-makers joined together to accelerate
the global and national response to viral hepatitis. The
result: the Glasgow Declaration on Viral Hepatitis, which
calls for comprehensive national plans to drive action to-
ward the elimination of viral hepatitis.
The success of the Summit centered on the involvement
of patients. Ahead of the official Summit, WHA organized
a pre-summit meeting for their members. This was a mo-
mentous occasion, as for the first time, our members—
many of which are small and under-resourced—were able
to meet each other, share experiences and feel part of a
wider, global network.
Patient groups compel us to confront the very human
side of hepatitis—the physical, emotional and financial tolls
that alter the lives of patients, those closest to them and
others in their communities. Patients’ personal insights are
crucial in helping policy-makers, service providers and
others understand the full impact of hepatitis and in help-
ing clarify the range of issues involved in disease prevention
and management. Other delegates in attendance, such as
those from the World Health Organization and national
ministries of health, had the unique opportunity in a public
forum to see disease control concepts and health policy ob-
jectives rigorously assessed from the perspective of lived
experience.
The Glasgow Declaration was one of the most import-
ant outcomes of the Summit because it cemented dele-
gates’ commitment to the goal of eliminating hepatitis B
and hepatitis C as a public health concern. The striking
enthusiasm with which delegates welcomed the Declar-
ation signified a collective determination and a growing
appetite in the hepatitis community for more coordinated
and collaborative efforts toward the goal of elimination.
This enthusiasm and commitment has continued among
all stakeholders since the Summit. Member States adopted
WHO’s first ever Global Health Sector Strategy on viral
hepatitis (GHSS) in May 2016, with its goal of elimination.
Then, on July 28, World Hepatitis Day 2016, the hepatitis
community launched NOhep, a global movement to
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Hepatitis Summit 2017 is being developed under the theme
of implementing the GHSS. Through continued commit-
ment, shared determination and collective action, we can
reach the goal of elimination by 2030.
Conclusions
The inaugural World Hepatitis Summit, a three day publicy
event jointly convened by the World Health Organization
(WHO) and the World Hepatitis Alliance (WHA) and
hosted by the Scottish Government and supported by
Glasgow Caledonian University and Health Protection
Scotland, was a significant event for the hepatitis commu-
nity. A one of its kind meeting which took place in Glasgow
in September 2015, the Summit brought together civil
society, patients, public health specialists, policy-makers,
and other key stakeholders and provided a collaborative
forum to advance the viral hepatitis agenda. Given the
success of this initiative it was decided that the Summit will
be run every two years by WHA and WHO in collabor-
ation with a different government each time (the next
World Hepatitis Summit is scheduled to take place from
1-3 November 2017 in Sao Paulo). In the light of the newly
adopted first-ever Global Health Sector Strategy on viral
hepatitis, which sets a goal of eliminating these diseases by
2030, and having in mind that to deliver elimination a coor-
dinated effort is needed, we concluded the World Hepatitis
Summit is key to accelerate action towards that goal.
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